Delivery Order SPE2DB20D3303-SPE2DB25FA2CG
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for ProQuad vials valued at $2,740.40 with an ultimate completion date of August 19, 2025. This firm fixed price, competitively awarded delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The order will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $6,055.26 to AmerisourceBergen Drug Corp for ProQuad vials on August 5, 2025, with an ultimate completion date of August 26, 2025. This competitively awarded, firm fixed price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The place of performance is located in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for ProQuad vials valued at $1,687.48, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026. The place of performance is located in Conshohocken,...
- The Defense Logistics Agency awarded a $16,543.30 delivery order to AmerisourceBergen Drug Corp for ProQuad vials, a combination vaccine product, with a completion date of August 21, 2025. This competitive award (no set-aside used) was issued under a firm fixed-price structure and represents a child contract under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $52,272.03 delivery order to AmerisourceBergen Drug Corp for ProQuad vials, with an ultimate completion date of August 25, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. ProQuad is a combination vaccine protecting against measles, mumps, rubella, and varicella, making...
- The Defense Logistics Agency awarded a $6,115.45 delivery order to AmerisourceBergen Drug Corp for ProQuad vials, with performance in Conshohocken, Pennsylvania and a completion date of July 31, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The prime vendor contract serves as a comprehensive global...
- The Defense Logistics Agency awarded a delivery order valued at $5,480.80 to AmerisourceBergen Drug Corp for ProQuad vials, a combination vaccine product. The contract, issued on September 10, 2025, with an ultimate completion date of October 1, 2025, represents a firm fixed-price delivery order with no set-aside designation. Performance will take place at the contractor's corporate office location in Conshohocken, Pennsylvania. This award is a child order under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,687.48 on August 29, 2025, for ProQuad vials, with an ultimate completion date of September 22, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The award was issued under AmerisourceBergen's existing Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999.99 billion comprehensive pharmaceutical support vehicle running through December...
- The Defense Logistics Agency awarded a $5,480.98 firm fixed price delivery order to AmerisourceBergen Drug Corp for ProQuad vials, with an ultimate completion date of May 12, 2025. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and running through December 2026. The place of performance is AmerisourceBergen's corporate office in...
- The Defense Logistics Agency awarded a delivery order valued at $1,687.48 to AmerisourceBergen Drug Corp for ProQuad vials with an ultimate completion date of October 3, 2025. This firm fixed-price delivery order, issued on September 12, 2025, represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The award was competitively awarded with no set-aside...
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB25FA2CGDelivery Order
The Defense Logistics Agency awarded a $5,426.92 delivery order to AmerisourceBergen Drug Corp for ProQuad vials, with an ultimate completion date of August 25, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The contract contains no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls within AmerisourceBergen's comprehensive pharmaceutical and medical supply distribution portfolio supporting federal military and healthcare systems. ProQuad, a combination vaccine used for immunization against measles, mumps, rubella, and varicella, represents the type of critical medical commodity the company routinely supplies through its DLA relationship. AmerisourceBergen's position as a primary pharmaceutical vendor for the Defense Health Agency and other federal health systems demonstrates its established capability to meet specialized medical procurement requirements across multiple therapeutic domains and product categories.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.4k | 8/4/25 |